On Monday, Viracta Therapeutics Inc (NASDAQ: VIRX) was 10.81% up from the session before settling in for the closing price of $0.21. A 52-week range for VIRX has been $0.13 – $1.31.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 134.94% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 35.23%. With a float of $28.01 million, this company’s outstanding shares have now reached $39.74 million.
In an organization with 40 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 55.42%, operating margin of -6397.02%, and the pretax margin is -5865.72%.
Viracta Therapeutics Inc (VIRX) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Viracta Therapeutics Inc stocks. The insider ownership of Viracta Therapeutics Inc is 29.53%, while institutional ownership is 13.00%. The most recent insider transaction that took place on Feb 27 ’24, was worth 2,493. In this transaction CFO and COO of this company sold 3,405 shares at a rate of $0.73, taking the stock ownership to the 102,306 shares.
Viracta Therapeutics Inc (VIRX) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 35.23% per share during the next fiscal year.
Viracta Therapeutics Inc (NASDAQ: VIRX) Trading Performance Indicators
You can see what Viracta Therapeutics Inc (VIRX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 0.76.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.10, a number that is poised to hit -0.16 in the next quarter and is forecasted to reach -0.56 in one year’s time.
Technical Analysis of Viracta Therapeutics Inc (VIRX)
Let’s dig in a bit further. During the last 5-days, its volume was 0.93 million. That was better than the volume of 0.77 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 69.46%. Additionally, its Average True Range was 0.03.
During the past 100 days, Viracta Therapeutics Inc’s (VIRX) raw stochastic average was set at 23.62%, which indicates a significant decrease from 78.41% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 106.45% in the past 14 days, which was higher than the 89.03% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.1911, while its 200-day Moving Average is $0.4950. However, in the short run, Viracta Therapeutics Inc’s stock first resistance to watch stands at $0.2499. Second resistance stands at $0.2671. The third major resistance level sits at $0.2823. If the price goes on to break the first support level at $0.2175, it is likely to go to the next support level at $0.2023. The third support level lies at $0.1851 if the price breaches the second support level.
Viracta Therapeutics Inc (NASDAQ: VIRX) Key Stats
There are 39,744K outstanding shares of the company, which has a market capitalization of 9.08 million. As of now, sales total 0 K while income totals -51,060 K. Its latest quarter income was 0 K while its last quarter net income were -10,550 K.
